• No results found

University of Groningen Clinical and molecular phenotyping of asthma and COPD Boudewijn, Ilse Maria

N/A
N/A
Protected

Academic year: 2021

Share "University of Groningen Clinical and molecular phenotyping of asthma and COPD Boudewijn, Ilse Maria"

Copied!
7
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

Clinical and molecular phenotyping of asthma and COPD

Boudewijn, Ilse Maria

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date: 2019

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Boudewijn, I. M. (2019). Clinical and molecular phenotyping of asthma and COPD. University of Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)

Clinical

and

molecular

phenotyping

of

asthma

and

COPD

(3)

Boudewijn, Ilse Maria

Clinical and molecular phenotyping of asthma and COPD

PhD dissertation, University of Groningen, The Netherlands

ISBN 978-94-6375-069-1

ISBN (electronic) 978-94-6375-179-7

© Copyright 2019 – Ilse Boudewijn, Groningen, The Netherlands

All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system or transmitted in any form or by any means, without prior permission of the author or, when appropriate, of the publisher of the publication or illustration material.

Cover design Evelien Jagtman | evelienjagtman.com

Lay-out Nikki Vermeulen | Ridderprint BV

Printing Ridderprint BV | www.ridderprint.nl

Printing of this thesis was financially supported by the University of Groningen, University Medical Center Groningen, Graduate School of Medical Sciences, GUIDE, department of pulmonary diseases UMCG, Longfonds, Stichting Astmabestrijding, ALK-Albello B.V., Boehringer Ingelheim B.V., Chiesi Pharmaceuticals B.V., Chipsoft B.V., Noord Negentig, Stethoscoopspecialist.nl and TEVA Netherlands B.V.

(4)

Clinical

and

molecular

phenotyping

of

asthma

and

COPD

Proefschrift

ter verkrijging van de graad van doctor aan de Rijksuniversiteit Groningen

op gezag van de

rector magnificus prof. dr. E. Sterken en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op woensdag 27 maart 2019 om 14.30 uur

door

Ilse Maria Boudewijn

geboren op 19 mei 1987 te Groningen

(5)

Promotores

Prof. dr. D.S. Postma Prof. dr. V. Guryev

Copromotor

Dr. M. van den Berge

Beoordelingscommissie

Prof. dr. C.E. Brightling Prof. dr. G.G. Brusselle Prof. dr. R. Gosens

Paranimfen

Dr. E. Hartmans Drs. S. Lubberts

(6)

TABLE OF CONTENTS

Chapter 1 General introduction 7

PART 1 CLINICAL PHENOTYPING

Chapter 2 Less small airway dysfunction in asymptomatic bronchial 29 hyperresponsiveness than in asthma

Chapter 3 Effects of ageing and smoking on pulmonary computed 45 tomography scans using parametric response mapping

Chapter 4 Extrafine compared to non-extrafine particle inhaled 55 corticosteroids in smokers and ex-smokers with asthma

Chapter 5 Predictors of clinical response to extrafine and non-extrafine 73 particle inhaled corticosteroids in smokers and ex-smokers

with asthma

Chapter 6 Bronchial provocation testing can be improved by using 83 dry powder adenosine instead of nebulized adenosine

monophosphate

PART 2 MOLECULAR PHENOTYPING

Chapter 7 Nasal gene expression differentiates COPD from controls and 93 overlaps bronchial gene expression

Chapter 8 Nasal gene expression changes with inhaled corticosteroid 113 treatment in asthma

Chapter 9 A novel role of bronchial microRNAs and long non-coding RNAs 133 in asthma remission

Chapter 10 Summary 155 Chapter 11 General discussion and future perspectives 163

Chapter 12 Nederlandse samenvatting 183

(7)

Referenties

GERELATEERDE DOCUMENTEN

We investigated small airway function assessed by spirometry and impulse oscillometry, as well as Borg dyspnea scores at baseline and during a methacholine provocation test in

Of interest, more small airways disease was independently of the extent of emphysema associated with higher RV/TLC% predicted, lower FEF 25-75 /FVC and lower FEV 1 /FVC values..

Since it may be particularly important to treat the small airways in smokers and ex- smokers with asthma, we hypothesized that treatment with extrafine particle ICS,

Furthermore, lower blood neutrophils were associated with higher improvements in PD 20 , independently of the level of blood eosinophils, in patients treated with QVAR, Clenil

6 Bronchial provocation testing can be improved by using dry powder adenosine instead of nebulized adenosine monophosphate..

Although ICS use confounds the primary analysis of nasal gene expression in this study, we addressed this issue by assessing whether COPD-associated nasal gene expression changes

A strength of our study is the comparison of changes in nasal gene expression after ICS treatment and ICS withdrawal, as well as the comparison of our findings with

Of interest, when integrating microRNA-, protein-coding RNA- and lncRNA expression by performing Bayesian network modeling, we identified a network characteristic of